Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
In short, CAIL wants to give skin back its 20-year-old appearance
The injection might cause a brief pinch or discomfort, but it is generally well-tolerated
The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide
Body Composition and Metabolic Parameters Research on component peptides revealed favorable effects on body composition and metabolic markers[10]: Significant reductions in waist circumference (10-15 cm reductions observed) Preferential visceral fat loss documented through imaging studies Preserved lean body mass relative to total weight loss in most studies Improved body composition ratios with fat mass reductions exceeding total weight loss percentages Type 2 Diabetes Research Glycemic Control Studies Investigations in type 2 diabetes models demonstrated robust glucose-lowering effects[11]: HbA1c reductions of 2.0-2.4% observed with GLP3 in phase 2 diabetes trials Fasting plasma glucose reductions of 40-60 mg/dL documented across dose ranges Improved continuous glucose monitoring parameters including time in range and glucose variability CagriSema combination achieved superior glycemic control compared to individual components Studies showed that 72% of participants with prediabetes reverted to normoglycemia with GLP3 treatment, suggesting potential diabetes prevention applications[12]
Kyrion, G., Boakye, K
Understand the science, benefits, risks and safe options in Los Angeles
US$ 21.16
US$ 28.13
US$ 24.37
US$ 22.48
